Immix Biopharma doses first patient in U.S. AL amyloidosis trial

seekingalpha07-09

Immix Biopharma (NASDAQ:IMMX) on Monday announced that the first patient had been dosed in its U.S. NEXICART-2 trial with NXC-201. The company added that the timing of the milestone was in line with ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2450080835?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-09 02:04","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2450080835","market":"fut","top_or_hot":-1,"title":"Immix Biopharma doses first patient in U.S. AL amyloidosis trial","media":"seekingalpha","content":"<div>\n<p>Immix Biopharma (NASDAQ:IMMX) on Monday announced that the first patient had been dosed in its U.S. NEXICART-2 trial with NXC-201.\nThe company added that the timing of the milestone was in line with ...</p>\n\n<a href=\"https://seekingalpha.com/news/4122687-immix-biopharma-doses-first-patient-in-us-al-amyloidosis-trial\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immix Biopharma doses first patient in U.S. AL amyloidosis trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmix Biopharma doses first patient in U.S. AL amyloidosis trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-09 02:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4122687-immix-biopharma-doses-first-patient-in-us-al-amyloidosis-trial><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Immix Biopharma (NASDAQ:IMMX) on Monday announced that the first patient had been dosed in its U.S. NEXICART-2 trial with NXC-201.\nThe company added that the timing of the milestone was in line with ...</p>\n\n<a href=\"https://seekingalpha.com/news/4122687-immix-biopharma-doses-first-patient-in-us-al-amyloidosis-trial\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B19Z6F94.USD","symbol_name":"Legg Mason Royce - US Smaller Companies A Acc USD","start_time":0,"source_url":"https://seekingalpha.com/news/4122687-immix-biopharma-doses-first-patient-in-us-al-amyloidosis-trial","article_id":"2450080835","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2450080835","pubTimestamp":1720461856,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Immix Biopharma  on Monday announced that the first patient had been dosed in its U.S. NEXICART-2 trial with NXC-201.The company added that the timing of the milestone was in line with its mid-2024 guidance.It also added that the data from its ex-US clinical trial reported at ASGCT 2024 showed a 92% overall response rate.Shares of IMMX dropped 7.20% to $2.19 during market hours.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B19Z6F94.USD":"Legg Mason Royce - US Smaller Companies A Acc USD","AL":"航空租赁公司","BK4572":"航空租赁","BK4104":"贸易公司与经销商","IMMX":"Immix Biopharma, Inc","BK4139":"生物科技"},"translate_title":"Immix Biopharma为美国AL淀粉样变性试验中的首例患者进行给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AL":1,"IMMX":1},"content_text":"Immix Biopharma (NASDAQ:IMMX) on Monday announced that the first patient had been dosed in its U.S. NEXICART-2 trial with NXC-201.\nThe company added that the timing of the milestone was in line with its mid-2024 guidance.\nIt also added that the data from its ex-US clinical trial reported at ASGCT 2024 showed a 92% overall response rate.\nShares of IMMX dropped 7.20% to $2.19 during market hours.\nPress release.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2450080835"}